Ose Immunotherapeutics Sa · EURONEXT:OSE
Ose Immunotherapeutics Sa — Investor Presentation (December 2022)
34 slides from Ose Immunotherapeutics Sa's investor presentation, December 2022
Slide 1: Breaking through the therapeutic ceiling with first-in-class immunotherapies
Breaking through the therapeutic ceiling with first-in-class immunotherapies December 2022
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains express or implied information and statements that might be deemed This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of forward-looking information and statements in respect of OSE Immunothera
Slide 3: Our Vision
Our Vision Breaking through the therapeutic ceiling with first-in-class immunotherapies 3
Slide 4: OSE Immunotherapeutics' strategic foundations
Corporate Highlights OSE Immunotherapeutics’ strategic foundations Diversified first-in-class product pipeline From Phase 1 to Phase 3, in monotherapy or in combination, in multiple indications Fully integrated biotech company Collaborations with strategic leaders • Mastering complex biology combine
Slide 5: OSE Immunotherapeutics pipeline
Corporate Highlights OSE Immunotherapeutics pipeline Combining a clinical portfolio of first-in-class assets with unique, highly productive R&D platforms Product candidate Targets Indication Research IND-enabling Phase I Phase II Phase III NSCLC Mono post-ICI Proprietary Neoepitopes NSCLC Combo 2L p
Slide 6: Strategic partners provide industry-leading clinical support and strong financial foundations
Corporate Highlights Strategic partners provide industry-leading clinical support and strong financial foundations Over €1.6bn in potential milestones; €121m* already received since 2016 Immuno-Oncology Potential Immuno-Inflammation Received OSE-172/BI 765063 FR-104/VEL-101 OSE-127/S95011 HNSCC and
Slide 7: An experienced executive leadership committee supported by an expert team
Corporate Highlights An experienced executive leadership committee supported by an expert team Nicolas Poirier, PhD Anne-Laure Dominique Costantini, Jean-Pascal Sophie Fay CEO, CSO Autret-Cornet MD Conduzorgues Chief External Affairs • 15+ years experience in Chief Financial Officer Chief Developmen
Slide 8: Our creative business model to produce sustained value
Corporate Highlights Our creative business model to produce sustained value Drive near-term value Advance our First-In-Class Build a sustainable business with Tedopi® R&D Pipeline & Platforms through partnerships • Expand EarlyUpAccess use in NSCLC 3L to €1.1bn • Myeloid Checkpoint platform • OSE-17
Slide 9: Our plan to build a leading immunotherapy company
Corporate Highlights Our plan to build a leading immunotherapy company Position Tedopi® as the best treatment option after ICI-failure in cancer patients Leverage the clinical advantage of anti-SIRPα in the DON’T Eat Me landscape in solid tumors Demonstrate lusvertikimab (OSE-127/S95011) clinical ac
Slide 10: Multiple short-term anticipated catalysts
Corporate Highlights Multiple short-term anticipated catalysts Readouts Readouts • TEDOPI® • TEDOPI® Regulatory update & Type C meeting Phase 2 combination trials • OSE-127/S95011 • OSE-172/BI 765063 Phase 2 trials in Sjögren & UC Phase 1/2 update • OSE-172/BI 765063 • OSE-279 Phase 1/2 update Phase
Slide 11: TEDOPI
TEDOPI® Bringing new hope to patients in the fight against ICI resistant NSCLC 11
Slide 12: An immunotherapy activating specific T-cells to revive anti-tumor response
TEDOPI® An immunotherapy activating specific T-cells to revive anti-tumor response • Unique combination of neoepitopes: small peptides deriving from tumor specific antigens* expressed in various cancers • Strong binding to HLA-A2 receptor (45% population) • Direct activation of tumor specific T-cell
Slide 13: Tedopi is a novel cancer vaccine with a strong biological rationale in post-ICI secondary resistance
TEDOPI® Tedopi® is a novel cancer vaccine with a strong biological rationale in post-ICI secondary resistance Shifting paradigms with cancer vaccine immunotherapy Primary (intrinsic) resistance No T-cell Patients who do not respond to ICIs refractory with a rapid disease progression tumors → Immune
Slide 14: Clinically meaningful benefit of Tedopi in monotherapy in NSCLC secondary resistance post-ICI
TEDOPI® Clinically meaningful benefit of Tedopi® in monotherapy in NSCLC secondary resistance post-ICI First randomized Phase 3, in this setting, with positive results vs. standard of care (SOC) OS rate at Overall Survival in PoI1 12 months Time to worsening ECOG PS ≥ 2 in Pol2 with 2d resistance in
Slide 15: Tedopi demonstrated better safety and quality of life profile
TEDOPI® Tedopi® demonstrated better safety and quality of life profile in patients with secondary resistant to ICI vs chemotherapy Significantly safer than SOC1 Quality of life (EORTC QLQ-LC13)3 Better Patient reported Outcomes for Global Health Arm A Tedopi® Arm B SoC Status, Role Functioning, Phys
Slide 16: Position Tedopi as the best treatment option after ICI-failure in cancer patients
TEDOPI® Position Tedopi® as the best treatment option after ICI-failure in cancer patients Confirmed Increased Agencies Awaited and MoA in Identification Survival granted innovative patients of population Compassionate mechanism of (T-cell with Decreased Access action post-IO response significant To
Slide 17: Target population estimated at 100k patients/year in NSCLC post-ICI (2nd line)
TEDOPI® Target population estimated at 100k patients/year in NSCLC post-ICI (2nd line) PD-(L)1 NSCLC market is growing (US$bn)1 Expending the potential in 2L • Lung cancer is the leading cause of post-ICI in G7 years cancer mortality worldwide, accounting for about 1.8m deaths each year.2 • NSCLC is
Slide 18: Tedopi delivers important clinical benefits vs competition
TEDOPI® Tedopi® delivers important clinical benefits vs competition Better QoL and safety profile in current landscape of late-stage drug development post CT-IO Company Immunotherapy ADC Target Multi-epitopes vaccine TKIs TIM-3 TROP2 CEACAM5 c-MET Current Study ATALANTE-1 MRTX-500 CONTACT-01 LEAP-00
Slide 19: Further additional potential clinical value in combination in NSCLC, PDAC and OC
TEDOPI® Further additional potential clinical value in combination in NSCLC, PDAC and OC Phase 2 ISS trials in combination with immunotherapy or chemotherapy treatments 2nd line post-ICI Maintenance treatment after standard treatment CombiTED1 – NSCLC TEDOVA2 – Ovarian cancer TEDOPaM3 – Pancreatic c
Slide 20: OSE-279: Proprietary PD-1 - value generator
OSE-279 OSE-279: Proprietary PD-1 - value generator High affinity PD-1 antibody, patent granted in US, Europe, China, Japan* Potential of combo with internal Backbone of the BiCKI® platform PD1 inhibition asset • Develop first-in-class Isotype control • Evaluate OSE-279 in monovalent bispecific comb
Slide 21: Our Innovative Discovery Engines
Our Innovative Discovery Engines Designed to deliver next generation first-in-class immunotherapies 21
Slide 22: Mastering complex biology - Two drug discovery platforms
Research Platforms Mastering complex biology - Two drug discovery platforms Fit for purpose design • Engineered proteins • Engineered antibodies Myeloid platform • Multi-specific / multi-functional therapeutics Myeloid Checkpoint Pro-resolutive mAb • Releasing the potential of • Triggering Resolutio
Slide 23: OSE-230 - Resolving inflammation is an active immune process
Research Platforms OSE-230 - Resolving inflammation is Pro- resolutive an active immune process mAb Restoration of homeostasis During chronic With ChemR23 inflammation agonistic mAbs Dying neutrophils send out OSE-230 limits recruitment, inflammatory signals (e.g. survival & NETosis of NETosis) that
Slide 24: CLEC-1 - Another way to not get eaten
Research Platforms CLEC-1 - Another way to not get eaten Myeloid checkpoint Blocking myeloid immune checkpoint from delivering another “Don’t-eat-me” signal Tumor homeostasis CLEC-1 mAbs disrupt tumor homeostasis2 Don’t Eat-Me Don’t Eat-Me SIRPα CD47 Anti-CLEC-1 mAbs increase killing efficacy of mye
Slide 25: Next-generation anti-PD1 bispecifics
Research Platforms Next-generation anti-PD1 bispecifics Anti-PD1 bispecifics Improving the quality of tumor-specific T-cell responses both in TME & Lymph Nodes Targeting the RIGHT T-cells… …at the right place Selective targeting of Tumor-specific PD-1+ T cells Selective Biodistribution in TME + Lymp
Slide 26: What's wrong with previous cytokine approaches?
Research Platforms What’s wrong with previous cytokine approaches? Anti-PD1/IL7 bispecifics Success takes time - it’s a marathon, not a sprint IL2/IL15 Sprinters legs IL7 Patient cancer journey Marathon runners legs It’s a marathon, not a sprint 26
Slide 27: Partnered clinical programs
Partnered clinical programs 27
Slide 28: SIRPα inhibition may have a synergistic antitumour effect when combined with ICIs
SIRPα program SIRPα inhibition may have a synergistic antitumour effect when combined with ICIs • Infiltrating myeloid cells promote immune evasion, and this has generated interest in The use of SIRPα myeloid-immune targets1,2 antagonists to enhance o The CD47–SIRPα interaction transduces inhibitory
Slide 29: Clinical development overview
SIRPα program Clinical development overview Most advanced clinically-tested SIRPα Dose Escalation Ongoing Accrual Expansion Studies Trial number NCT03990233 NCT04653142 NCT052494263 Key takeaways from dose Phase Ia Ia Ib Ib Ib escalation N 50 18 40 36 150 • Safety OSE-172 No hematotoxicity reported,
Slide 30: FR-104/VEL-101 CD28 antagonist in transplantation
FR104 / VEL-101 FR-104/VEL-101 CD28 antagonist in transplantation Phase 1 results: Selective CD28 antagonist FR-104 Ongoing Phase 1 / 2 trial persistently reduces antibody responses in kidney transplantation CD28 antagonist2 (FR104) • Good safety1 - demonstrated o Absence of clinical or biological e
Slide 31: OSE-127/S95011 - Differentiated MoA as full IL-7 receptor antagonist
Lusvertikimab OSE-127/S95011 - Differentiated MoA as full IL-7 receptor antagonist License option to Servier after Phase 2 Tackling the fuel of memory T-lymphocytes while sparing Tregs A differentiated and highly qualified candidate • IL7 produced by inflamed tissues sustain T-cell survival and chro
Slide 32: Summary
Summary a 2 OSENLN2
Slide 33: Investment Highlights
Corporate Highlights Investment Highlights Promising clinical data from the lead asset Tedopi® Compelling product • Met primary overall survival endpoint in monotherapy in PoI pivotal NSCLC post-ICI study • Significant better Safety profile & Quality of Life with positive Net Treatment Benefit versu
Slide 34: Breaking through the therapeutic ceiling with first-in-class immunotherapies
Breaking through the therapeutic ceiling with first-in-class immunotherapies Immuno-Oncology & Immuno-Inflammation Head Office Paris Office 22, boulevard Bénoni Goullin 10, Place de Catalogne 44200 Nantes, France 75014 Paris, France Company Information: http://ose-immuno.com/en/
OSE Immunotherapeutics — Investor Presentation (December 2022) on 6ix